A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.
Health economics and policy academics from the London School of Hygiene & Tropical Medicine (LSHTM), writing in the Journal of the Royal Society of Medicine, warn that if the NHS England Innovative Medicines Fund (IMF) is not implemented appropriately, it risks disincentivising the generation of essential evidence and could shift the financial burden from the pharmaceutical industry to the public finances.
A new fund to fast-track patient access to potentially valuable new medicines may incentivise the pharmaceutical industry to develop high priced drugs for rare diseases with weak evidence on clinical benefits.
Health economics and policy academics from the London School of Hygiene & Tropical Medicine (LSHTM), writing in the Journal of the Royal Society of Medicine, warn that if the NHS England Innovative Medicines Fund (IMF) is not implemented appropriately, it risks disincentivising the generation of essential evidence and could shift the financial burden from the pharmaceutical industry to the public finances.
